(0.11%) 5 523.25 points
(0.13%) 39 896 points
(0.25%) 19 800 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.29%) $2 337.50
(0.12%) $29.56
(0.32%) $1 005.00
(-0.01%) $0.931
(-0.03%) $10.53
(-0.02%) $0.788
(-0.85%) $87.25
28.30% $ 0.0399
Live Chart Being Loaded With Signals
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 2 761 |
Średni wolumen | 8 835 |
Kapitalizacja rynkowa | 10.46M |
EPS | $-0.140 ( Q4 | 2024-05-15 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
NLS Pharmaceutics AG Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
NLS Pharmaceutics AG Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-11 408.00 (0.00 %) |
EPS: | $-0.320 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-11 408.00 (0.00 %) |
EPS: | $-0.320 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-11 408.00 (0.00 %) |
EPS: | $-0.840 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej